Across TCGA pan-cancer cohorts, ZNF346 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated ZNF346 data layer compared with 22 for mass-spec protein and 4 for mutation status.
The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher ZNF346 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated ZNF346 expression acts as an unfavorable survival marker, although some lineages such as GBM and LSCC show a favorable association.
PDAC, GBM, and LSCC are the cancer types where ZNF346 mass-spec protein most reproducibly stratifies survival.